Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cisplatin - Privo Technologies

Next Previous
Drug Profile

Cisplatin - Privo Technologies

Alternative Names: Cisplatin transmucosal patch - Privo Technologies; Cisplatin Transmucosal System; PRV 111; PRV-211; PRV111 patch; PRV211 patch

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Privo Technologies
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer; Mouth neoplasm; Carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours; Squamous cell cancer
  • Phase I/II Head and neck cancer

Most Recent Events

  • 16 Oct 2023 Privo Technologies initiates a phase II clinical trial in Squamous cell cancer in USA (Transmucosal) (NCT05893888)
  • 09 Sep 2022 Privo Technologies receives direct-to-phase II SBIR grant from National Cancer Institute (NCI) for cisplatin development in Cervical cancer
  • 24 Aug 2022 Privo Technologies plans a phase III trial for Squamous cell cancer (Transmucosal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top